Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment

Yuling Huang1, Xin Li2* and Lina Yang1*

Abstract
Since December 2019, the coronavirus (COVID-19) pandemic has imposed huge burdens to the whole world, seriously affecting global economic growth, and threatening people’s lives and health. At present, some therapeutic regimens are available for treatment of COVID-19 pneumonia, including antiviral therapy, immunity therapy, anticoagulant therapy, and others. Among them, injection of mesenchymal stem cells (MSCs) is currently a promising therapy. The preclinical studies and clinical trials using MSCs and small extracellular vesicles derived from MSCs (MSC-sEVs) in treating COVID-19 were summarized. Then, the molecular mechanism, feasibility, and safety of treating COVID-19 with MSCs and MSC-sEVs were also discussed.

Keywords: Mesenchymal stem cells, Small extracellular vesicles, COVID-19, Molecular mechanism

Introduction
Coronavirus disease 2019 (COVID-19) has become an important issue that threatens human health worldwide. Since 2019, more than 2.6 x 10^8 people have been diagnosed as having COVID-19 and more than 5 x 10^6 died of the disease according to the latest statistics from the World Health Organization (WHO) (https://covid19.who.int/). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the direct cause of COVID-19, and it is transmittable by means of direct transmission, aerosol transmission, and contact transmission. Severe or fatal COVID-19 patients mainly show pathological features including diffuse alveolar damage, and changes related to coagulation disorders and/or hemodynamic depression [1]. Apart from affecting lung, SARS-CoV-2 can also infect pancreas, kidney, heart, nerve, and so on [2, 3]. Symptoms of COVID-19 range from asymptomatic infections to inducing critically ill symptoms including fever, headache, dry cough, diarrhea, hypoxemia, joint aches, metabolic acidosis, ARDS, multiple organ dysfunction, etc. [4]. While vaccination can prevent COVID-19 to some extent, the constantly emerging SARS-CoV-2 variants and mutations seem to reduce the protection afforded by vaccines [5]. In that context, timeous diagnosis and treatment have become a key to improving prognosis of COVID-19 patients [6]. Currently, therapeutic measures available for treatment of COVID-19 include respiratory support and drug therapy, such as plasma therapy, antiviral drug therapy, immune-mediated therapy, glucocorticoid therapy, metabolic support and nutrition therapy, stem cell therapy, artificial liver therapy, lung transplantation. [7]. Hence, developing new and effective treatment methods has become a focus among numerous researchers.

Transplantation of mesenchymal stem cells (MSCs) is a promising therapeutic strategy for a variety of disorders. Previous research has proven that MSCs are beneficial to treatment of many diseases. The International Society

*Correspondence: xuanfeng7890@163.com; yanglina1984@163.com
1 Departments of Geriatrics, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, People’s Republic of China
2 Departments of Infectious Disease, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning, People’s Republic of China

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
for Cellular Therapy (ISCT) defines MSCs according to the following three standards: plastic adhesion, specific surface markers, and trilineage differentiation [8]. MSCs are derived from bone marrow (BMMSCs), adipose tissue (ADMSCs), human umbilical cord Wharton’s-jelly (UC-MSCs or WJ-MSCs), etc. Many studies indicated that MSCs play their roles by differentiation and releasing various mediators, such as all kinds of soluble trophic factors and extracellular vesicles (EVs) to modulate immunity, anti-inflammatory, anti-apoptotic, and antiviral [9, 10], which are the main mechanisms of current regimes to combat COVID-19. From basic to clinics, MSCs have been widely verified the potential to alleviate ARDS which plays an important role in COVID-19 [11, 12].

Compared to MSCs, EVs have a greater therapeutic potential due to nanoparticles that can penetrate the blood–brain barrier and reach injury locations, as well as lesser immunogenicity and tumorigenicity. EVs can be divided into small EVs (sEVs) with size of < 200 nm and medium/large EVs (m/lEVs) with size of > 200 nm in the Minimal Information for Studies of Extracellular Vesicles 2018 [13]. Functioning as a transporter, sEVs carry proteins, deoxyribonucleic acids (DNAs), messenger ribose nucleic acids (mRNAs), micro-ribose nucleic acids (miRNAs), etc., specifically secreted by metrocyte [14]. sEVs wrapped by lipid bilayers can stably deliver those aforementioned key messages [15]. This explains why research on sEVs focuses on three aspects: use in treatment, serving as a drug carrier, and functioning as a biomarker.

Santos and Almeida proposed that sEVs can be used as a vaccine against COVID-19 [16]. Fu and Xiong found that the engineered sEV system that is used for targeted delivery of potential antiviral drugs to specific tissues in vivo has therapeutic potential for SARS-CoV-2 infections [17]. Krishnamachary et al. predicted the severity of COVID-19 disease using sEVs and lEVs [18]. Currently, many preclinical studies and clinical trials of MSCs and sEVs in treating COVID-19 are under investigation. Also, the molecular mechanism, feasibility, and safety of treating COVID-19 with MSCs and small extracellular vesicles derived from MSCs (MSC-sEVs) were discussed in this review.

**Current research into the use of MSCs against COVID-19**

At present, several early-phase clinical studies indicated that MSCs can combat COVID-19 by inhibition of cytokine storm, anti-inflammatory action, and immunoregulation. MSCs used in clinical trials are mainly UC-MSCs, and there are also MSCs derived from menstrual blood (MenSCs) or BMMSCs. Many clinical trials have validated the feasibility, safety, and tolerance of MSCs and MSC-sEVs in treating COVID-10 (Table 1).

**Clinical trials of MSCs against COVID-19**

Currently, more and more clinical trials are underway to study the use of MSCs in treating COVID-19. After being transplanted to COVID-19 patients, whether MSCs will be infected by SARS-CoV-2 or maintain their therapeutic effect is the premise of using MSCs. Schäfer et al. unveiled that MSCs are tolerant to SARS-CoV-2 infections and can maintain their immunoregulatory potential, which supports their potential applicability in the treatment of COVID-19 [19]. Through evaluation, Wedzinska et al. found the possible changes in biology of MSCs in an active inflammatory environment: no matter what the aerobic condition is, the external inflammatory environment will not induce phenotypic changes in WJ-MSCs or cause disruption of proliferation; it will also not inhibit the secreting characteristics of these MSCs, so that they can be used to fight acute inflammation [20].

MSCs have been recognized as safe and feasible in treatment of patients with COVID-19 pneumonia and many clinical trials confirmed that the intravenous injection of MSCs will relieve clinical features and not induce severe adverse effects. It has been reported that a severe SARS-CoV-2 infected patient separately diagnosed in Changsha (Hunan Province) [21] and Liaocheng (Shandong Province) [22], received MSC infusion with inflammation-related indicators and the pulmonary function was significantly improved, while no adverse reaction associated with MSC treatment occurred. In addition, after applying UC-MSC infusion as an adjuvant therapy for a critically severe COVID-19 patient, Zhu et al. found that the absolute number of lymphocytes increased significantly and even multiple organ functions were ameliorated while no obvious side effect occurs [23]. Feng et al. conducted four rounds of transplantation of UC-MSCs to 16 severe and critically severe COVID-10 patients and recorded adverse events from registration to the 28th day of treatment. Results showed that the oxygenation index was enhanced and mortality relatively lowered, however, there was no infusion-related adverse events or anaphylaxis [24]. Meng et al. conducted a parallel, controlled non-randomized phase 1 clinical trial, to evaluate the safety of infusion of UC-MSCs in treating moderate and severe COVID-19 patients with pulmonary diseases, and observed that the levels of cytokine reduced, symptoms improved, and no severe adverse events related to the infusion [25]. Furthermore, Shi et al. recruited 101 severe COVID-19 patients with lung injury to receive UC-MSCs. The lung solid component lesions resolved faster and the integrated reserve capability improved. All adverse events in the observation period
Table 1  Clinical trials of MSCs and MSC-sEVs against COVID-19

| Study Phase and Type                  | Severity of COVID-19 | Number Enrolled | MSC/MSC-sEV source | Dosage       | Frequency     | Assessment of the efficacy                                                                 | Adverse Primary Safety Outcome                                                                 | Refs. |
|--------------------------------------|----------------------|-----------------|--------------------|--------------|--------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-------|
| A case report                         | Critical             | 1               | UC-MSCs            | $1 \times 10^6$ cells/kg | Days 0 and 3 | Inflammation-related indicators significantly improved; the cytokine storm was dampened and the NK cells were modulated | No infusion or allergic reactions, secondary infections, or treatment-related adverse events were found | [21]  |
| A case report                         | Severe               | 1               | WJ-MSCs            | $1 \times 10^6$ cells/kg | Single dose  | The pulmonary function and symptoms were significantly improved                            | No acute infusion-related or allergic reactions were observed                                  | [22]  |
| A case report                         | Critical             | 1               | UC-MSCs            | $1 \times 10^6$ cells/kg | Single dose  | Inflammatory reaction was improved, and lung function and multiple organ functions were improved | No obvious side effects were observed                                                      | [23]  |
| A small sample, single arm, pilot trial | Severe; critical     | 16              | UC-MSCs            | $1 \times 10^8$ cells   | Single dose  | The oxygenation index was improved, mortality relatively lowered; radiological presentations improved, lymphocyte count recovered and cytokine levels decreased | No infusion-related or allergic reaction                                                   | [24]  |
| A Phase 1 parallel non-randomized assigned, controlled, trial | Moderate; severe     | 18              | UC-MSCs            | $3 \times 10^7$ cells   | Days 0, 3, and 6 | The levels of cytokine reduced; symptoms improved                                          | No serious UC-MSC infusion-associated adverse events were observed                             | [25]  |
| A Phase 2 randomized, double-blind, placebo-controlled trial | Severe               | 101             | UC-MSCs            | $4 \times 10^7$ cells   | Days 0, 3, and 6 | Accelerated resolution of lung solid component lesions and the integrated reserve capability improved | No MSC infusion-related adverse events                                                      | [26]  |
| A prospective cohort follow-up study  | Severe               | 28              | UC-MSCs            | $2 \times 10^6$ cells/kg | Single dose  | Accelerated partial pulmonary function recovery and improved HRQL                           | No obvious adverse effects were observed in the UC-MSC group after 3 months                  | [27]  |
| A Phase 1/2 trial                     | Severe; critical     | 210             | UC-MSCs            | $1-2 \times 10^6$ cells/kg | Single dose  | The SaO2 parameter tended to improve; significantly higher survival was observed in patients who underwent UC-MSCs | No adverse effects were observed related to infusion or allergic reactions, secondary infection, or life-threatening adverse events | [28]  |
| A Phase 1 double-blind, multi-center randomized controlled trial | Critical             | 40              | UC-MSCs            | $1 \times 10^6$ cells/kg | Single dose  | The survival rate increased; there was no significant difference regarding the period of intubation and the period from intubation | MSCs were well tolerated with no life-threatening complications or acute allergic reactions during the administration | [29]  |
| A Phase 1/2a double-blind randomized controlled trial | Mild-to-moderate; moderate-to-severe | 24 | UC-MSCs            | $100 \pm 20 \times 10^6$ cells | Days 0 and 3 | The levels of key inflammatory molecules were reduced; time to recovery was significantly shortened | No serious adverse events related to MSC infusion were observed                             | [30]  |
| Phase 1                              | Severe               | 5               | WJ-MSCs            | $150 \times 10^6$ cells | Days 0, 3, and 6 | Inflammation was reduced; COVID-19 antibody tests rose the total score of zonal involvement in both lungs was improved | No serious complications were observed except the headache in one of them                 | [31]  |
| Study Phase and Type | Severity of COVID-19 | Number Enrolled | MSC/MSC-sEV source | Dosage | Frequency | Assessment of the efficacy | Adverse Primary Safety Outcome | Refs. |
|---------------------|----------------------|-----------------|--------------------|--------|-----------|-----------------------------|--------------------------------|-------|
| A case series        | Critical              | 11              | PL-MSCs, UC-MSCs   | $200 \times 10^6$ cells | Days 0, 2, and 4 | Respiratory symptoms improved and inflammatory conditions reduced | No serious adverse events were reported 24–48 h after the cell infusions | [32]  |
| A non-randomized assigned, controlled trial | Severe | 23             | BM-MSCs           | $1 \times 10^6$ cells/kg | 2–3 times | Pulmonary function and overall outcome improved | No significant side effects after MSC infusion | [33]  |
| 2 case reports       | Severe                | 2               | MenSCs            | $1 \times 10^6$ cells/kg | Days 0, 1, and 3 | Lung function improved | Not find obvious adverse reactions | [34]  |
| A Phase 1 multi-center, open-label, non-randomized, parallel, controlled trial | Severe; critical 18 | 44             | MenSCs            | $9 \times 10^7$ cells | Days 0, 2, and 4 | The mortality significantly lowered; alleviating the breathing difficulties and reducing the symptoms of ARDS or respiratory dyspnea | The incidence of most adverse events did not differ between the groups, experimental group, and control group | [35]  |
| A case               | Severe                | 1               | UC-MSCs           | $1 \times 10^6$ cells/kg | Days 0, 2, and 8 | Inflammatory, respiratory, thrombotic, and renal parameters improved | No adverse events occurred | [41]  |
| A prospective double phase 1/2 controlled trial | Moderate; critical 20 | 30             | WJ-MSCs           | $3 \times 10^6$ cells/kg | Days 0, 3, and 6 | All the indicators of anti-inflammation, antifibrosis signs in the lungs, and immune-modulatory markers improved | No adverse or serious adverse events occurred related to the MSC therapy | [42]  |
| A case series        | Severe; critical 8    | 31              | UC-MSCs           | $1 \times 10^6$ cells/kg | 1–3 times | SARS-CoV-2 PCR results of 30 patients (96.8%) became negative after a mean time of 10.7 days; laboratory parameters, hypoxia, immune reconstitution, and cytokine storms improved | No adverse events were attributable to intravenous transplantation of UC-MSCs | [43]  |
| A Phase 1/2a random controlled trial | Severe | 24             | UC-MSCs           |                                              | 1–3 times | Survival, serious adverse events-free survival, and time to recovery significantly improved | Serious adverse events-free | [44]  |
| A Phase 1, single-arm, non-randomized, parallel trial | Healthy | 24             | ADMSC-sEVs        | $2–16 \times 10^8$ particles | Once inhalation | Improved survival rate to 80% at 96 h in P. aeruginosa-induced murine lung injury model by decreasing lung inflammation and histological severity | No serious adverse events were observed within 7 days | [78]  |
| A prospective nonblinded non-randomized trial | Mild; severe 20; critical 3 | 24             | BM-MSC-sEVs       | $15 \times 10^6$ cells/kg | Single dose | Patients’ clinical status and oxygenation improved, laboratory values revealed significant improvements in absolute neutrophil count, and acute phase reactants declined | No adverse events were observed within 72 h of ExoFlo administration | [79]  |

Many clinical trials have validated the feasibility, safety, and tolerance of MSCs in treating COVID-19. MSCs used in clinical trials are mainly UC-MSCs or WJ-MSCs, and there are also MenSCs or BMMSCs. As for the dose of intravenous infusion of MSCs, the majority of studies adopt three doses, each with 106 cells/kg in 100 mL of normal saline. MSCs: mesenchymal stem cells; UC-MSCs or WJ-MSCs: MSCs are derived from human umbilical cord Wharton’s jelly; BM-MSCs: MSCs are derived from bone marrow; MenSCs: MSCs derived from menstrual blood; MSC-sEVs: small extracellular vesicles derived from MSCs.
of the randomized double-blinded placebo-controlled phase 2 trial (NCT04288102) are unrelated to the UC-MSC intervention [26]. Different from the short-term observation of adverse reactions, Feng et al. conducted a three-month post-discharge follow-up. They found that vein transplantation of UC-MSCs facilitates recovery of some lung function and improves the health-related quality of life, while no patients show adverse reactions after discharge [27].

As for the dose of intravenous infusion of MSCs, there remains a lack of a unified standard. The majority of studies adopt three doses, each with $10^6$ cells/kg in 100 mL of normal saline. There are also clinical trials using single and two injections, which may be dependent on the severity of patients. N et al. performed UC-MSC treatment on 210 severe and critically severe patients through intravenous injection of single-dose clinical-grade UC-MSCs ($1 \times 10^6$ to $2 \times 10^6$ cells/kg). They found that repeated doses can be applied for seriously ill patients, to support the treatment primarily through the anti-inflammatory and immunoregulatory effects [28]. In a randomized controlled trial, 20 patients received single intravenous infusion of UC-MSCs ($1 \times 10^6$ cells/kg). The significant decreases in interleukin 6 and the reducing number of circulating peripheral blood immune cells suggest the recession of the cytokine storm and progress in clinical improvement [29]. In a double-blinded 1/2a phase randomized controlled trial, the subjects in the UC-MSCs treated group received two intravenous infusions ($100 \pm 20 \times 10^6$ cells) and no serious adverse events associated with the infusion of UC-MSCs were observed [30]. Five severe COVID-19 patients received three intravenous injections of WJ-MSCs (each $150 \times 10^6$ cells) every three days and no severe complications related to WJ-MSCs were found [31]. In a phase 1 clinical trial, Hashemian et al. demonstrated the safety, feasibility, and tolerance of multiple high-dose MSCs from allogenic placenta and UC-MSCs in treating critically severe acute respiratory distress syndrome (ARDS) patients induced by COVID-19 [32].

Almost all of the aforementioned research uses UC-MSCs to treat COVID-19. This is possibly because UC-MSCs are easily isolated and cultured, have strong proliferation ability, and are derived from a relatively pure source with less chance of contamination. BMSCs and MenMSCs have also been used to combat SARS-CoV-2 in clinical trials, in addition to UC-MSCs. Häberle et al. treated five of 23 severe COVID-19 patients with ARDS by infusion of BM-MSCs. In this way, the lung functions and overall prognosis of the patient population are also improved [33]. Tang et al. revealed that allogeneic MenMSCs also improve lung function through the anti-inflammatory effect on injured lung [34]. Results of a multicenter open-label non-randomized parallel-controlled phase I clinical trial show that transplantation of MenSCs can significantly reduce the mortality of COVID-19 induced by severe SARS-CoV-2 infections [35]. It is noteworthy that a preclinical trial reveals that human dental pulp stem cells can regulate generation of cytokines in COVID-29 patients through in vitro peripheral blood mononuclear cells [36].

To treat SARS-CoV-2 infections, the combination of injection of MSCs and other therapies seems to have better treatment effects. Peng et al. confirmed that UC-MSCs and serum of convalescent patients have collaborative features in inhibiting cytokine storm, facilitating repair of lung injury, and recovering lung function [37]. Senegaglia et al. reported treatment of severe COVID-19 patients with the combination of monoclonal antibody tocitizumab and UC-MSCs, with no adverse reaction [38]. Commonly seen complications of COVID-19 patients include thrombotic complication [39]. Intravenous injection of MSCs is also likely to induce blood coagulation events, while O’Rourke et al. found that intravascular thrombosis is inhibited by delivery of MSCs using a preclinical trial system involving an in vitro bioreactor [40].

After being exposed to external stimulation, numerous cytokines are released, which induces hyperimmunity of the organism and finally affects various systems. Inhibitions of cytokine storm and anti-inflammation are the main mechanisms of action of MSCs against COVID-19. Ciccocioppo et al. conducted immunological research on a patient hospitalized due to COVID-19 pneumonia and treated with UC-MSCs: they found that UC-MSCs may be beneficial to developing an anti-inflammatory and protective environment, which can inhibit the cytokine storm and help recovery of the pulmonary alveolar capillary barrier, instead of having a direct antiviral effect [41]. Adas et al. proved that, in addition to reducing mortality and shortening the length of stay in ICU, WJ-MSCs also play a special role in treatment of patients with critically severe COVID-19: MSC transplantation seems to control the cytokine storm and reduce the progression of the disease [42]. Guo et al. suggested that treatment with UC-MSCs can recover oxygenation in hospitalized severe COVID-19 patients and down-regulate the cytokine storm while not inducing any response to infusion [43]. In a double-blinded phase 1/2a randomized controlled trial ($n = 24$), Kouroupis et al. determined the plasma concentrations of sTNFR2, TNFα, and TNFβ. Their results indicated that sTNFR2 exerts an inflammation inhibiting effect when mediating influences of UC-MSCs on the plasma concentrations of TNFα and TNFβ [44].
Possible molecular mechanisms of MSCs against COVID-19

After being infected with SARS-CoV-2, the body develops diverse immune responses and inflammation to combat COVID-19 [45, 46]. ACE2 and TMPRSS2 are common pathways for SARS-CoV-2 to infect many organs [47]. Meanwhile, SARS-CoV-2 can damage various organs by virtue of specific factors, such as Tau protein in brain [48], kidney injury molecule-1 (KIM-1) [49], and NLRP3 inflammasome [50]. A coincidence arises whereby numerous studies confirmed that MSCs can influence these common and specific factors, thus protecting corresponding organs. Therefore, MSCs may be able to combat COVID-19 by altering these processes (Fig. 1).

Common: ACE2 and TMPRSS2

SARS-CoV-2 enters cells through interactions of its spike (S) protein with angiotensin converting enzyme 2 (ACE2) receptor on cells. SARS-CoV-2 is internalized with the aid of transmembrane serine proteinase 2 (TMPRSS2) [47]. ACE2 and TMPRSS2 are distributed extensively across various organs, including the lung [51], small intestine [52, 53], heart [54], and brain [55], and kidney [56], so that SARS-CoV-2 can affect various organs [57]. The low expressions of ACE2 and TMPRSS2 in MSCs provide a premise for treating COVID-19. Leng et al. found that MSCs are ACE2(-) and TMPRSS2(-) through gene expression profiling, which implies that MSCs are not infected by SARS-CoV-2 [58]. By evaluating MSCs derived from amniotic membrane, umbilical cord blood, UC-MSCs, ADMSCs, and BMMSCs, Avanzini et al. found that ACE2 and TMPRSS2 are expressed in Calu-3 cell strains in lung, rather than in all MSCs [59]. Hernandez et al. confirmed the negative expression of ACE2 and low expression of TMPRSS2 in 24 batches of UC-MSCs [60]. Furthermore, Desterke et al. proposed that early cultured UC-MSCs express even lower ACE2 [61]. Intriguingly, Wei et al. proposed that ACE2 over-expressing MSCs can moderate COVID-19 lung injury in vivo and in vitro by decreasing inflammatory factors and pyroptosis factors [62].

Specific: Tau protein, KIM-1, NLRP3 inflammasomes, and mucosal-associated invariant T cells

SARS-CoV-2 can damage the body through some specific mechanisms (Tau protein in brain, KIM-1 in kidney, and NLRP3 inflammasomes), in addition to the common ones (ACE2 and TMPRSS2). Overall, MSCs and sEVs protect the body through the above mechanisms to against COVID-19 (Table 2). SARS-CoV-2 can enter the central nervous system through olfactory mucosa [63] The hyperphosphorylation of Tau protein is one of the features of neuroinvasion of SARS-CoV-2. The S protein of SARS-CoV-2 interacts with amyloid proteins, such as Ab, a-synuclein, Tau, prion, and TDP-43 RRM [64], which lead to changes in distribution of Tau from axon to somatic cells, hyperphosphorylation, and apparent neuronal death [48]. By coincidence, Jia et al. repaired damaged nerve cells by down-regulating hyperphosphorylated Tau protein, reversing spinal loss, and facilitating synaptic plasticity using UC-MSCs [65]. Other researchers also reduced the hyperphosphorylation of Tau protein in the mouse model of Alzheimer’s disease by intravenous administration of MSCs [66, 67].

A retrospective analysis indicated that SARS-CoV-2 directly infects kidney and mediates renal tubular acidosis and AKI [68]. Tanase et al. identified KIM-1 as a potential marker of kidney injury [69]. Yang et al. believed that KIM-1 is a potential receptor of SARS-CoV-2, and it mediates and exacerbates the vicious circle of kidney infections by SARS-CoV-2 [49]. Coincidentally, Aussel et al. reduced the KIM-1 level on kidney slices by infusion of MSCs [70].

SARS-CoV-2 can induce inflammation in many ways. Ratajczak et al. found that the interplay between ACE2 receptor and SARS-CoV-2 S protein in human vascular and hematopoietic stem cells activates NLRP3 inflammasomes, thus facilitating inflammatory responses. If NLRP3 inflammasomes are activated excessively, pyroptosis may be triggerred [50]. MSCs were found to inhibit the activation of NLRP3 inflammasomes in many diseases. In degeneration of intervertebral discs, Xia et al. reported that MSCs play an anti-inflammatory role by inhibiting activation of inflammatory mediators and NLRP3 inflammasomes via exosomes [71]. Sun et al. proved that UC-MSCs enhanced insulin resistance by suppressing inflammation in rats with type-2 diabetes mediated by NLRP3 inflammasomes [72]. Research results of Li et al. indicated that MSCs control the activation of NLRP3 by facilitating the Hippo pathway of macrophages and regulating XBP1 [73]. Miteva et al. also confirmed that MSCs limit the adverse outcome of cardiac and systemic NLRP3 inflammasome activation in Coxackievirus B3-induced myocarditis [74].

T cells are one of the core immune cells in the defense against SARS-CoV-2. Mucosal-associated invariant T (MAIT) cells are immune cells in viral inflammation. Hubrack et al. showed that SARS-CoV-2 activates and depletes MAIT cells that can kill bacteria or cells infected by viruses. In COVID-19 patients, the granzyme B, IFN-γ, TNF-α, and perforin of MAIT cells were found in lowered proportions [75]. MSCs significantly induce activated phenotypes and then regulate activation of MAIT cells by up-regulating expressions of CD69, granzyme B,
IFN-γ, and TNF-α but not by influencing proliferation of MAIT cells in bone marrow, liver, and intestinal tissue [76].

**MSC-sEVs Against COVID-19**

The ISCT and the International Society for Extracellular Vesicles (ISEV) have recognized the potential of MSC-sEVs and sEVs from other cells in treatment of COVID-19. Research by Vaka et al. revealed that the paracrine production and viability of BMMSC, heart-derived cells, and UC-MSCs under COVID-19 ARDS cytokines are not altered, laying the groundwork for MSC-sEVs to treat COVID-19 [77].

At present, there are a few clinical research on the treatment of COVID-19 with MSC-sEVs (Table 2). Despite this, existing clinical trials all confirmed that MSC-sEVs are safe and effective. Shi et al. performed complex research to evaluate the preclinical efficacy and safety of clinical-grade aerosolized allograft ADMSC-sEVs. On the one hand, the aerosol inhalation of ADMSC-sEVs protects mice against severe pneumonia; on the other hand, it is safe for healthy volunteers and has no severe adverse
### Table 2: Possible molecular mechanisms of MSCs against COVID-19

| Molecular | Mechanisms of SARS-CoV-2 | Refs | Mechanisms of MSCs | Involved organs/diseases | Involved cell types | Origin of MSCs | Refs. |
|-----------|--------------------------|------|-------------------|--------------------------|---------------------|----------------|-------|
| Common molecular | | | | | | | |
| ACE2 and TMPRSS2 | SARS-CoV-2 enters target cells via its S protein which helps the virus to target ACE2 binding sites of cells, and the priming activator TMPRSS2 of ACE2 assists internalization of the virus | [51] | ACE2(-) and TMPRSS2(-) protect MSCs from infecting by SARS-CoV-2 | Lung | Immune cells | BMMSCs, ADMSCs, UC-MSCs, etc | [58–61] |
| | | | | | | | |
| Specific molecular | Tau protein | [64] | Regulate hyperphosphorylated Tau protein | Brain | Nerve cells | UC-MSCs | [66–67] |
| KIM-1 | KIM-1, a potential receptor of SARS-CoV-2, mediates and exacerbates the vicious circle of kidney infections by the virus | [49] | Reduce the KIM-1 level | Kidney | | BMMSCs | [70] |
| NLRP3 inflammasomes | The interplay between ACE2 receptor and SARS-CoV-2 S protein activates NLRP3 inflammasomes, thus facilitating inflammatory responses | [50] | Inhibit activation of inflammatory mediators and NLRP3 inflammasomes via exosomes | Intervertebral disc | Nucleus pulposus cells | BMMSCs | [71] |
| | | | | | | | |
| MAIT cells | SARS-CoV-2 activates and depletes MAIT cells that can kill bacteria or cells infected by viruses | [75] | Induce activated phenotypes and regulate activation of MAIT cells by up-regulating expressions of CD69, granzyme B, IFN-γ, and TNF-α | Infection, metabolic disorders, and inflammatory diseases | MAIT cells | ADMSCs | [76] |

SARS-CoV-2 can damage the body through some specific mechanisms (Tau protein in brain, KIM-1 in kidney, and NLRP3 inflammasomes), in addition to the common ones (ACE2 and TMPRSS2). Overall, MSCs and sEVs protect the body through the above mechanisms to against COVID-19.

ACE2: angiotensin converting enzyme 2; TMPRSS2: transmembrane serine protease 2; KIM-1: kidney injury molecule-1; MAIT cells: mucosa-associated invariant T; MSCs: mesenchymal stem cells; BMMSCs: MSCs are derived from bone marrow; UC-MSCs or WJ-MSCs; ADMSCs: MSCs derived from adipose tissue.
effects (NCT04313647) [78]. However, the authors used human platelet lyase for sEV preparation and PEG methods to isolate sEVs which is controversy. In hospitalized patients with severe COVID-19, single intravenous injection of MSC-sEVs significantly improves the hypoxia, immune reconstitution, and cytokine storm and there is no adverse reaction related to the infusion of sEVs [79]. The absence of blinding, randomization, and the limited sample size require further clinical studies to investigate safety and efficacy of sEVs treating COVID-19. The dosage, the methods of isolation and many other issues of above trials have been summarized in Table 1. Many ongoing clinical trials of MSC-sEV treatment in COVID-19 pneumonia and ARDS (NCT04493242, NCT05354141) may provide evidence to support MSC-sEV as a cell-free therapy for COVID-19.

According to some preclinical research, MSC-sEVs appear to alleviate COVID-19 via antiviral (preventing viral duplication and transmission) and anti-inflammatory effects. Chutipongtanate et al. suggested that MSC-sEVs exhibit anti-SARS-CoV-2 effects by inducing infected lung epithelial cells to decrease viral replication and production/release of infectious virions [80]. Park et al. proved that MSC-sEVs and five main miRNAs (miR-92a-3p, miR-26a-5p, miR-23a-3p, miR-103a-3p, and miR-181a-5p) significantly inhibit duplication of SARS-CoV-2 and have anti-inflammatory activity in vitro [81]. In addition to the antiviral effect, MSC-sEVs control inflammation to treat COVID-19. Khanh et al. proved that WJ-sEVs have the potential to decrease the cytokine storm in patients with chronic inflammation and viral infections by in vitro experiments [82]. In the Silico analysis, Schultz et al. proposed that miRNAs carried by MSC-EVs (including MSC-sEVs) serve as potential multiple targets for treatment of COVID-19, which reduces the excessive generation of inflammatory factor and chemokines, blood coagulation cascade, and apoptosis [83]. Complement and neutrophil axis can amplify and perpetuate the cytokine storm in severe COVID-19 patients. Recent research determine that MSC-sEVs can specifically inhibit they through CD59[84].

Conclusions
In summary, SARS-CoV-2 can infect the body through ACE2 and TMPRSS2, as well as Tau protein, KIM-1, NLRP3 inflammasomes, and MAIT cells. MSCs and MSC-sEVs show the possibility in treating COVID-19 via the molecular mechanism mentioned above. MSCs have been approved as a drug for clinical treatment of Crohn's disease complicated by intestinal fistula and graft-versus-host disease. Numerous early-phase studies have verified the feasibility, effectiveness, and safety of MSCs and MSC-sEVs, while their optimal sources and specific medication regimens still remain an open question.

From existing research, UC-MSCs are most widely used and they are mainly administered through continuous intravenous injection (1 × 10^6 cells/kg). Meanwhile, improvement of the extraction, culture, and proliferation of MSCs can also enhance the treatment effect. For example, 3D cell culture strengthens the angiogenesis and immunoregulatory functions of MSCs [85]. Moreover, the acquisition of abundant and scalable MSC-sEVs and sEVs damage during extraction are also matters of concern. Lee et al. combined bioreactor culture with tangential flow filtration and size exclusion chromatography to produce highly-pure bioactive sEVs carrying hetIL-15/lactadherin [86], providing a clue for acquiring a large amount of MSC-sEVs. As for possible contamination, Good Manufacturing Practice (GMP) criteria and the critical quality control points (CQCP) may aid in evaluating the safety of clinical-grade MSCs and MSC-sEVs.

There are some other limitations to this topic. Firstly, in light of MSC conservation and transportation, it is critical to assess the differences in therapeutic properties between thawed and fresh MSCs. Secondly, preclinical and clinical study endpoints should include other laboratory metrics such as SARS-CoV-2 viral titers in addition to clinical features. Thirdly, most clinical trials have a short follow-up, which cannot observe the effect of MSCs and MSC-sEVs on long-term complications of COVID-19. The other issue is the administration of other drugs which may affect the anti-inflammation and immunomodulatory properties of MSCs and MSC-sEVs.

Taken together, more extensive randomized controlled research needs to be undertaken to reveal the detailed pathophysiological mechanism underlying the treatment of COVID-19 with MSCs and MSC-sEVs. Clinically, further phase 3 clinical trials should be conducted to ascertain the potential of MSCs and MSC-sEVs in treating COVID-19.

Abbreviations
COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; MSCs: Mesenchymal stem cells; BM-MSCs: MSCs derived from bone marrow; ADMSCs: MSCs derived from adipose tissue; UC-MSCs: MSCs derived from human umbilical cord; WJ-MSCs: MSCs derived from Wharton’s-jelly; EVs: Extracellular vesicles; sEVs: Small EVs; MSC-sEVs: Small extracellular vesicles derived from MSCs; 5 protein: Spike protein; ACE2: Angiotensin converting enzyme 2; TMPRSS2: Transmembrane serine protease 2; KIM-1: Kidney injury molecule-1; IFN: Interferon; AKI: Acute kidney injury; MAIT: Mucosal-associated invariant T cells; MenSCs: MSCs derived from menstrual blood; ARDS: Acute respiratory distress syndrome.

Acknowledgements
We are grateful to the National Natural Science Foundation of China (Grant No. 81970663) and the Natural Science Foundation of Liaoning Province (Grant No. 2019-B5-277).
Liu D, Kou X, Chen C, Liu S, Liu Y, Yu W, et al. Circulating apoptotic bodies as a predictor of COVID-19 severity. J Control Release. 2020;317:108712.

Delorey TM, Ziegler CGK, Heimberg G, Normand R, Yang Y, Segerstolpe Å, et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature. 2021;595(7865):107–13.

Huang G, Gong T, Wang G, Wang J, Guo X, Cai E, et al. Timely diagnosis of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther. 2021;10(9):e12117.

Schäfer R, Spohn G, Bechtel M, Bojkova D, Baer PC, Kuqi S, et al. Human mesenchymal stromal cells are resistant to SARS-CoV-2 infection under steady-state, inflammatory conditions and in the presence of SARS-CoV-2-infected cells. Stem Cell Rep. 2021;16(3):419–27.

Wedzinska A, Figiel-Dabrowska A, Kozlowska H, Sarnowska A. The effect of proinflammatory cytokines on the proliferation, migration and secretory activity of mesenchymal stem/stromal cells (iW-MSCs) under 5% O2 and 21% O2 culture conditions. J Clin Med. 2021;10(9):1813.

Zhang Q, Huang K, Lv J, Fang X, He J, Lv A, et al. Case report: Human umbilical cord mesenchymal stem cells as a therapeutic intervention for a critically ill COVID-19 patient. Front Med (Lausanne). 2021;8:691329.

Zhang Y, Ding J, Ren S, Wang W, Yang Y, Li S, et al. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther. 2020;11(1):207.

Zhu Y, Zhu R, Liu K, Li X, Chen D, Bai D, et al. Human umbilical cord mesenchymal stem cells for adjuvant treatment of a critically ill COVID-19 patient: a case report. Infect Drug Resist. 2020;13:3295–300.

Feng Y, Huang J, Wu J, Xu Y, Chen B, Jiang L, et al. Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: a pilot study. Cell Prolif. 2020;53(12):e12947.

Meng F, Xu R, Wang S, Xu Z, Zhang C, Li Y, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5(1):172.

Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021;6(1):58.

Feng G, Shi L, Huang T, Ji N, Zheng Y, Lin H, et al. Human umbilical cord mesenchymal stem cell treatment of severe COVID-19 patients: a 3-month follow-up study following hospital discharge. Stem Cells Dev. 2021;30(15):773–81.

Dauletova M, Hafsan H, Mahhengam N, Zekiy AO, Ahmad M, Siahmansouri H. Mesenchymal stem cell along with exosomes as a novel cell-based therapy for COVID-19: a review study. Clin Immunol. 2021;226:108712.

Dílogo IH, Aditianingsih DG, Sugianto A, Burhan E, Damayanti T, Sitompul PA, et al. Umbilical cord mesenchymal stem cells as a therapeutic intervention for critically ill COVID-19 patients: a randomized controlled trial. Stem Cells Transl Med. 2021;10(9):1279–87.

Lanzoni G, Linetsky E, Correa D, Messinger CS, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660–73.

Saleh M, Vaesi AA, Aliannejad R, Sohrabpour AA, Kaei SZF, Shadnoush M, et al. Cell therapy in patients with COVID-19 using Wharton's jelly mesenchymal stem cells: a phase 1 clinical trial. Stem Cell Res Ther. 2021;12(1):410.

Hashemian SR, Aliannejad R, Zarrabi M, Soleimani M, Vosough H, Hosseini SE, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021;12(1):91.

Häberle H, Maguina H, Lang P, Gloeckner H, Körner A, Koeppen M, et al. Mesenchymal stem cell therapy for severe COVID-19 ARDS. J Intensive Care Med. 2021;36(6):681–8.

Tang L, Jiang Y, Zhu M, Chen L, Zhou X, Zhou C, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med. 2020;14(5):664–73.
Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M, et al. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: an exploratory clinical trial. Clin Transl Med. 2021;11(2):e297.

Crocì S, Bonacini M, Doli G, Massari M, Faccolongo N, Nagnetti E, et al. Human dental pulp stem cells modulate cytokine production in vitro by peripheral blood mononuclear cells from coronavirus disease 2019 patients. Front Cell Dev Biol. 2020;8:e609204.

Peng H, Gong T, Huang X, Sun X, Luo H, Wang W, et al. A synergistic role of in vivo cointervention of plasma in mesenchymal stem cells and the treatment of severely ill COVID-19 patients: a clinical report. Stem Cell Res Ther. 2020;11(1):291.

Senegaglia AC, Rebelatto CLK, Franck CL, Lima JS, Boldrini-Leite LM, Daga DR, et al. Combined use of tocilizumab and mesenchymal stromal cells in the treatment of severe COVID-19 case-report. Cell Transplant. 2021;30:106897212110088.

Oliva A, Cammissotto V, Cerami R, Ferro D, Miele MC, De Angelis M, et al. Low-grade endotoxemia and thrombosis in COVID-19. Clin Transl Gastroenterol. 2021;12(6):e00348.

O'Rourke B, Nguyen S, Tilles AW, Bynum JA, Cap AP, Parekkadan B, et al. Mesenchymal stromal cell delivery via an ex vivo bioartifact preclinical test system attenuates clot formation for intravascular application. Stem Cells Transl Med. 2021;10(8):883–94.

Ciccióippio RL, Grebennik D, Astori G, Bernardi M, Bozza A, Chiaregato K, et al. The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia. Stem Cell Res Ther. 2021;12(1):316.

Adas G, Cukurova Z, Yasar KY, Yilmaz R, Ikicsanac N, Kasapoglu P, et al. The systemic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial. Cell Transplant. 2021;30:6368972121104492.

Guo Z, Chen Y, Luo X, He X, Zhang Y, Wang J. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia. Crit Care. 2020;24(1):420.

Kouroupis D, Lanzoni G, Lintentzky E, Messinger CS, Wishnek MS, Leheero C, et al. Umbilical cord-derived mesenchymal stem cells modulate TNF and soluble TNF receptor 2 (sTNFR2) in COVID-19 ARDS patients. Eur Respir Med Pharmacol Sci. 2021;25(12):4435–8.

Zhang Z, Zheng Y, Niu Z, Zhang B, Wang C, Yao X, et al. SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination. Cell Death Differ. 2020;28(9):765–77.

Arif M, Paniskaki K, Blazquez-Navamo A, Doevelaar A, Seibert FS, Holzer B, et al. COVID-19-induced ARDS is associated with decreased frequency of activated memory/effector T cells expressing CD11a(+). Mol Ther. 2020;28(12):2691–702.

Jackson CB, F zumar M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):1–20.

Ramani A, Müller L, Osternann PN, Gabriel E, Abida-Islam P, Müller-Schiffmann A, et al. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 2020;39(20):e106230.

Yang C, Zhang Y, Zeng X, Chen H, Chen Y, Yang D, et al. Kidney injury molecule-1 is a potential receptor for SARS-CoV-2. J Mol Cell Biol. 2021;13(3):185–96.

Ratążczak MZ, Bukoj K, Ciechanowicz A, Sieńkiewicz K, Cymer M, Maricz W, et al. SARS-CoV-2 entry receptor ACE2 is expressed on very small CD45(-) precursors of hematopoietic and endothelial cells and in response to virus spike protein activates the NLRP3 inflammasome. Stem Cell Res Rev. 2021;17(1):266–77.

Damiani S, Fiorentino M, De Palma A, Foschini MP, Lazzarotto T, Gabrielli L, et al. Pathological post-mortem findings in lungs infected with SARS-CoV-2. J Pathol. 2021;253(1):31–40.

Suárez-Fariñas M, Tokuyama M, Wei G, Huang R, Livanos A, Jha D, et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardio myocytes. Cardiovasc Res. 2020;116(12):2207–15.

Imperio GE, Lye P, Mughis H, Hamada H, Blosie E, Lye SJ, et al. Hypoxia alters the expression of ACE2 and TMPRSS2 SARS-CoV-2 cell entry mediators in HMEC/D3 brain endothelial cells. Microvasc Res. 2021;138:104232.

Dey A, Sen S, Mauilk U. Unveiling COVID-19-associated organ-specific cell types and cell-specific pathway cascade. Brief Bioinform. 2021;22(2):914–23.

Sato T, Ueha R, Goto T, Yamauchi A, Kondo K, Yamashita T. Expression of ACE2 and TMPRSS2 proteins in the upper and lower aerodigestive tracts of rats: implications on COVID-19 infections. Laryngoscope. 2021;131(3):E952–9.

Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE(2) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–28.

Avanzini MA, Mura M, Percivalle E, Bastaroli F, Croce S, Valsecchi C, et al. Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. Stem Cells Transl Med. 2021;10(4):636–42.

Hernandez JJ, Beaty DE, Fruehwirth LL, Lopes Chaves AP, Riordan NH. Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells. J Transl Med. 2021;19(1):1149.

O’Rourke B, Nguyen S, Tilles AW, Bynum JA, Cap AP, Parekkadan B, et al. Mesenchymal stem cell therapy in severe COVID-19 pneumonia. The Journal of Clinical Investigation. 2020;130(2):306–15.

Olivier M, Kamen B, Walker A, Kieslich D, Castelino D, Rizzuto G, et al. Treatment of COVID-19 lung injury by inhibiting pyroptosis. iScience. 2020;22(4):104046.

Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, et al. Human kidney is not a target for SARS-CoV-2 infection and contains low ACE2 and TMPRSS2 levels. Int J Mol Sci. 2020;21(14):5238.

Fang B, Tao M, Gu C, Zheng L, et al. Mesenchymal stem cells derived from umbilical cord blood ameliorate rat cardiac injury. Cell Transplant. 2020;29(10):1714–31.

Anft M, Paniskaki K, Blazquez-Navamo A, Doevelaar A, Seibert FS, Hölzer B, et al. COVID-19-induced ARDS is associated with decreased frequency of activated memory/effector T cells expressing CD11a(+) cells. Mol Ther. 2020;28(12):2691–702.

Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):1–20.

Ramani A, Müller L, Osternann PN, Gabriel E, Abida-Islam P, Müller-Schiffmann A, et al. SARS-CoV-2 targets neurons of 3D human brain organoids. EMBO J. 2020;39(20):e106230.

Yang C, Zhang Y, Zeng X, Chen H, Chen Y, Yang D, et al. Kidney injury molecule-1 is a potential receptor for SARS-CoV-2. J Mol Cell Biol. 2021;13(3):185–96.

Ratążczak MZ, Bukoj K, Ciechanowicz A, Sieńkiewicz K, Cymer M, Maricz W, et al. SARS-CoV-2 entry receptor ACE2 is expressed on very small CD45(-) precursors of hematopoietic and endothelial cells and in response to virus spike protein activates the NLRP3 inflammasome. Stem Cell Res Rev. 2021;17(1):266–77.

Damiani S, Fiorentino M, De Palma A, Foschini MP, Lazzarotto T, Gabrielli L, et al. Pathological post-mortem findings in lungs infected with SARS-CoV-2. J Pathol. 2021;253(1):31–40.

Suárez-Fariñas M, Tokuyama M, Wei G, Huang R, Livanos A, Jha D, et al. Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2-related disease. Gastroenterology. 2021;160(1):287–301.e20.

Zang R, Gomez Castro MF, McCune BT, Zeng Q, Rothlauf PW, Sonnek NM, et al. TMPRSS2 and TMPRSS2 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020;5(44):eabc3582.

Bojkova D, Wagner JUG, Shumilakivska M, Aslan GS, Saleem U, Hansen A, et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardio myocytes. Cardiovasc Res. 2020;116(14):2207–15.
74. Miteva K, Pappritz K, Sosnowski M, El-Shafeey M, Müller I, Dong F, et al. Mesenchymal stromal cells inhibit NLRP3 inflammasome activation in a model of Coxsackievirus B3-induced inflammatory cardiomyopathy. Sci Rep. 2018;8(1):2820.

75. Hubrack S, Al-Nesf MA, Agrebi N, Raynaud C, Khattab MA, Thomas M, et al. In vitro Interleukin-7 treatment partially rescues MAIT cell dysfunction caused by SARS-CoV-2 infection. Sci Rep. 2021;11(1):14090.

76. Ye G, Wang P, Xie Z, Cao Q, Li J, Zheng G, et al. Autophagy-mediated activation of mucosal-associated invariant T cells driven by mesenchymal stem cell-derived IL-15. Stem Cell Rep. 2021;16(4):926–39.

77. Vaka R, Khan S, Ye B, Risha Y, Parent S, Courtman D, et al. Direct comparison of different therapeutic cell types susceptibility to inflammatory cytokines associated with COVID-19 acute lung injury. Stem Cell Res Ther. 2022;13(1):20.

78. Shi MM, Yang QY, Monsel A, Yan JY, Dai CX, Zhao JY, et al. Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipogenic mesenchymal stromal cells-derived extracellular vesicles. J Extracell Vesicles. 2021;10(10):e12134.

79. Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev. 2020;29(12):747–54.

80. Chutipongtanate S, Kongsomros S, Pongsakul N, Panachan J, Khowsaitrusit L, Pattanapanyasat K, et al. Anti-SARS-CoV-2 effect of extracellular vesicles released from mesenchymal stem cells. J Extracell Vesicles. 2022;11(3):e12201.

81. Park JH, Choi Y, Lim CW, Park JM, Yu SH, Kim Y, et al. Potential therapeutic effect of micromas in extracellular vesicles from mesenchymal stem cells against SARS-CoV-2. Cells. 2021;10(9):2393.

82. Khanh VC, Fukushige M, Chang YH, Hoang NN, Yamashita T, Obata-Yasukoa M, et al. Wharton's jelly mesenchymal stem cell-derived extracellular vesicles reduce SARS-CoV2-induced inflammatory cytokines under high glucose and uremic toxin conditions. Stem Cells Dev. 2021;30(15):758–72.

83. Schultz IC, Bertoni APS, Wink MR. Mesenchymal stem cell-derived extracellular vesicles carrying miRNA as a potential multi target therapy to COVID-19: an in silico analysis. Stem Cell Rev Rep. 2021;7(2):341–56.

84. Loh JT, Zhang B, Teo JMH, Lai RC, Choo ABH, Lam KP, et al. Mechanism for the attenuation of neutrophil and complement hyperactivity by MSC exosomes. Cytotherapy. 2022;24:711.

85. Doron G, Temenoff JS. Culture substrates for improved manufacture of mesenchymal stromal cell therapies. Adv Healthc Mater. 2021;10(15):e2100016.

86. Lee JH, Ha DH, Go HK, Youn J, Kim HK, Jin RC, et al. Reproducible large-scale isolation of exosomes from adipose tissue-derived mesenchymal stem/stromal cells and their application in acute kidney injury. Int J Mol Sci. 2020;21(13):4774.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.